Atrial Fibrillation Also called: AF, Afib

Clinical Trial Finder

Many patients with atrial fibrillation are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

Condition:   Atrial Fibrillation
Interventions:   Drug: Edoxaban;   Drug: Clopidogrel;   Drug: Prasugrel;   Drug: ticagrelor
Sponsors:   Daiichi Sankyo Inc.;   European Cardiovascular Research Institute;   Kompetenznetz Vorhofflimmern e.V.;   Chiltern International Inc.
Not yet recruiting - verified August 2016

Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France

Condition:   Atrial Fibrillation
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Vitamin K antagonists;   Drug: dabigatran (Pradaxa)
Sponsor:   Bayer
Not yet recruiting - verified August 2016

Leukocytes and Perioperative Cardio Vascular Events

Condition:   Elective Non-cardiac Surgery
Intervention:  
Sponsor:   University Hospital Heidelberg
Not yet recruiting - verified August 2016

Self-management of Anticoagulation Treatment

Conditions:   Atrial Fibrillation;   Venous Thromboembolism;   Artificial Heart Valve
Intervention:   Other: Training
Sponsor:   University of Bergen
Completed - verified August 2016

The Educational Effectiveness for Atrial Fibrillation Patients Under Warfarin Treatment

Condition:   Atrial Fibrillation
Intervention:   Other: Patient education related Warfarin
Sponsor:   Chang Gung Memorial Hospital
Completed - verified July 2016

Catheter Ablation and Rate Control of Atrial Fibrillation in Patients With Heart Failure

Conditions:   Catheter Ablation;   Rate Control;   Heart Failure;   Atrial Fibrillation
Intervention:  
Sponsor:   Nanjing Medical University
Active, not recruiting - verified August 2016

Low Fluoroscopy Afib Ablation Registry

Condition:   Atrial Fibrillation
Intervention:   Procedure: Ablation
Sponsors:   Stanford University;   Beacon Medical Group;   Allegheny Health Network Research Institute
Recruiting - verified August 2016

Scandinavian Multicenter Study to Advance Risk Stratification in Heart Disease- Ventricular Arrhythmias

Conditions:   Ventricular Arrhythmias;   Implantable Defibrillator User;   Biological Markers;   Heart Disease
Intervention:  
Sponsors:   University Hospital, Akershus;   Helse Stavanger HF;   University of Oslo
Recruiting - verified August 2016

Treatment Convenience in Patients Treated With Dabigatran for Stroke Prophylaxis in Atrial Fibrillation (SPAF)

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified August 2016

Comparison of Outcomes After Left Atrial Appendage Closure or Oral Anticoagulation in Patients With Atrial Fibrillation

Condition:   Atrial Fibrillation
Intervention:   Other: Questionnaire
Sponsor:   University Hospital Inselspital, Berne
Enrolling by invitation - verified August 2016

Effect of Remote Ischemic Preconditioning on Electrophysiological and Biomolecular Parameters in Non-valvular Paroxysmal Atrial Fibrillation: RIPPAF Study

Condition:   Atrial Fibrillation
Interventions:   Procedure: Remote ischemic preconditioning (RIPC);   Procedure: sham-intervention
Sponsor:   Jedrzej Kosiuk
Recruiting - verified August 2016

Patient Convenience Study- NIS RELATE

Condition:   Atrial Fibrillation
Interventions:   Drug: Pradaxa (dabigatran);   Drug: Vitamin K antagonist
Sponsor:   Boehringer Ingelheim
Recruiting - verified August 2016

Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in China: A Non-interventional Study

Condition:   Stroke
Intervention:   Drug: Rivaroxaban (Xarelto, BAY 59-7939)
Sponsor:   Bayer
Recruiting - verified August 2016

Length of Stay in NVAF Patients Hospitalized and Initiated With Dabigatran or Warfarin in Japan

Condition:   Atrial Fibrillation
Interventions:   Drug: Dabigatran;   Drug: Wafrarin
Sponsor:   Boehringer Ingelheim
Not yet recruiting - verified August 2016

Patient Convenience Study (RE-SONANCE)

Conditions:   Atrial Fibrillation;   Stroke
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified August 2016

Exercise Training in Patients With Atrial Fibrillation (OPPORTUNITY Study)

Condition:   Atrial Fibrillation
Interventions:   Behavioral: moderate-intensity continuous exercise training;   Behavioral: high-intensity interval training
Sponsor:   Ottawa Heart Institute Research Corporation
Recruiting - verified August 2016

ImplemeNtation oF demOnstration pRoject for Health systeMs: Atrial Fibrillation (INFORM-AF) Part 1

Condition:   Atrial Fibrillation
Intervention:  
Sponsors:   Duke University;   Boehringer Ingelheim;   Daiichi Sankyo Inc.
Recruiting - verified August 2016

Anticoagulation Preference by AF Patients Study

Condition:   Atrial Fibrillation
Interventions:   Other: VKAs;   Other: NOACs including Rivaroxaban (Xarelto, BAY59-7939);   Other: Edoxaban;   Other: Apixaban;   Other: Dabigatran-etexilate
Sponsor:   Bayer
Recruiting - verified August 2016

Unipolar Atrial Electrogram Modification Combined to the Contact Force Sensing Technology for Pulmonary Vein Isolation

Conditions:   Atrial Fibrillation;   Arrhythmia
Intervention:  
Sponsors:   Hôpital Privé Les Franciscaines;   Clinique St Pierre, Perpignan, France;   Clinique Ambroise Paré, Neuilly sur Seine, France;   Hôpital Privé Clairval, Marseille, France;   Infirmerie Protestante de Lyon, Lyon, France;   Centre Hospitalo-Universitaire de Brabois, Vandoeuvre Les Nancy, France;   Centre Hospitalier Régional Universitaire Montpellier;   Paris Cardiovascular Research Center (Inserm U970), Paris, France;   Clinique Pasteur
Completed - verified August 2016

aMAZE Study: LAA Ligation Adjunctive to PVI for Persistent or Longstanding Persistent Atrial Fibrillation

Condition:   Atrial Fibrillation
Interventions:   Device: LARIAT + PVI;   Device: Pulmonary Vein Isolation
Sponsor:   SentreHEART, Inc.
Recruiting - verified August 2016

Laser Ablation Study for trEatment of atRial Fibrillation (LASER)

Condition:   Atrial Fibrillation
Interventions:   Device: Laser ablation;   Device: RF ablation
Sponsors:   Hospital Clinic of Barcelona;   CardioFocus
Recruiting - verified August 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care drugs
Sponsor:   Bayer
Recruiting - verified August 2016

Ablation Verses Anti-arrhythmic Therapy for Reducing All Hospital Episodes From Recurrent Atrial Fibrillation

Conditions:   Heart Failure;   Recurrent Atrial Fibrillation
Interventions:   Procedure: AVATAR-AF ablation;   Drug: Anti-Arrhythmic therapy;   Procedure: Conventional AF ablation
Sponsor:   Imperial College London
Recruiting - verified August 2016

Atrial Fibrillation General Registry

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   European Society of Cardiology
Recruiting - verified August 2016

A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

Condition:   Acute Coronary Syndromes
Interventions:   Drug: Apixaban;   Drug: vitamin K antagonist;   Drug: Acetylsalicylic acid;   Other: Acetylsalicylic acid placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer;   Duke Clinical Research Institute
Recruiting - verified August 2016

SL-AF Trial - (Six Lead Identification of Atrial Fibrillation [AF])

Condition:   Atrial Fibrillation
Intervention:   Device: RhythmPadGP
Sponsor:   Cardiocity Limited
Completed - verified August 2016

Left Atrial Geometry and Outcomes After Atrial Fibrillation Ablation

Conditions:   Atrial Fibrillation;   Recurrence
Intervention:  
Sponsors:   Hospital Clinic of Barcelona;   Germans Trias i Pujol Hospital;   Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau;   Hospital del Mar;   Hospital Virgen de la Salud;   Hospital San Carlos, Madrid;   Fundación para la Investigación del Hospital Clínico de Valencia;   Complexo Hospitalario Universitario de Vigo;   Puerta de Hierro University Hospital
Active, not recruiting - verified August 2016

Randomized Evaluation of Atrial Fibrillation Treatment With Focal Impulse and Rotor Modulation Guided Procedures

Condition:   Persistent Atrial Fibrillation
Interventions:   Procedure: Standard PVI Ablation;   Procedure: FIRM-Guided Procedure and PVI
Sponsor:   Abbott Electrophysiology
Recruiting - verified August 2016

Drug Persistence/Adherence in Patients Treated With Dabigatran or VKA for Stroke Prevention in Non Valvular Atrial Fibrillation (SPAF)

Condition:   Atrial Fibrillation
Interventions:   Drug: Dabigatran etexilate;   Drug: Phenprocoumon
Sponsor:   Boehringer Ingelheim
Recruiting - verified August 2016

Early Post-marketing Study of Eliquis (Apixaban)

Condition:   Non-valvular Atrial Fibrillation (NVAF)
Intervention:   Drug: Apixaban
Sponsor:   Bristol-Myers Squibb
Withdrawn - verified August 2016

Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)

Condition:   Atrial Fibrillation
Interventions:   Drug: Apixaban;   Drug: Parenteral heparin and/or oral Vitamin K antagonist
Sponsors:   Pfizer;   Bristol-Myers Squibb
Recruiting - verified August 2016

Second Study to Assess Different Ablation Strategies in Achieving Long-Term Arrhythmia Control in Patients With Persistent or Long Standing Persistent Atrial Fibrillation

Condition:   Atrial Fibrillation
Intervention:   Other: Pulmonary Vein Isolation procedure
Sponsor:   University of Pennsylvania
Terminated - verified August 2016

Oral Anticoagulation Therapy Pilot Study

Condition:   Paroxysmal Atrial Fibrillation
Interventions:   Other: Off OAT Group (Test);   Other: On OAT Group (Control)
Sponsor:   Biosense Webster, Inc.
Recruiting - verified August 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Germany)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified August 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified August 2016

Anticoagulant Utilization Pattern

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified August 2016

AMPLATZER Cardiac Plug (ACP) Registry-Long Term Follow-up Protocol

Conditions:   Atrial Fibrillation;   Left Atrial Appendage;   Stroke
Intervention:   Device: Amplatzer Cardiac Plug
Sponsor:   St. Jude Medical
Completed - verified August 2016

SPARK: Safety Study of Pradaxa in Atrial Fibrillation Patients by Regulatory Requirement of Korea

Condition:   Atrial Fibrillation
Intervention:   Drug: Pradaxa (Dabigatran etexilate mesilate)
Sponsor:   Boehringer Ingelheim
Recruiting - verified August 2016

CardioSmart Points

Log in to Check Your Balance
and Go Shopping

Learn how to earn more CardioSmart Points